In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer

被引：0
|
作者：
Caenepeel, Sean [1 ]
Zhang, Nancy [1 ]
Wang, Ling [1 ]
Norman, Mark H. [1 ]
Burgess, Terri [1 ]
Radinsky, Robert [1 ]
Kendall, Rick [1 ]
Freeman, Daniel [1 ]
Hughes, Paul E. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2805
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2805
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AMG 511, a potent and selective class I PI3K inhibitor, suppresses the growth of Kras mutant lung tumors in mice
    Estrada, Juan
    Ungersma, Sharon
    Kaufman, Stephen
    Yerby, Brittany
    Zhang, Nancy
    Freeman, Daniel
    Hughes, Paul
    Silva, Matthew
    Coxon, Angela
    [J]. CANCER RESEARCH, 2012, 72
  • [2] AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models
    Zhang, Nancy
    Caenepeel, Sean
    Wang, Ling
    Norman, Mark
    Kendall, Richard
    Burgess, Terri
    Radinsky, Robert
    Hughes, Paul
    Freeman, Daniel J.
    [J]. CANCER RESEARCH, 2012, 72
  • [3] Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ
    Allen, Rodger A.
    Brookings, Daniel C.
    Powell, Mark J.
    Delgado, Jean
    Shuttleworth, Lindsay K.
    Merriman, Mark
    Fahy, Ian J.
    Tewari, Roohi
    Silva, John P.
    Healy, Louise J.
    Davies, Gareth C. G.
    Twomey, Breda
    Cutler, Rona M.
    Kotian, Apoorva
    Crosby, Andrea
    McCluskey, Gillian
    Watt, Gillian F.
    Payne, Andrew
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 361 (03): : 429 - 440
  • [4] A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells.
    Keles, Erhan
    Borsari, Chiara
    Sriramaratnam, Rohitha
    Schafer, Thorsten
    Wymann, Matthias P.
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [5] Identification of AMG 511 as a selective class I phosphoinositide 3-kinase inhibitor
    Wurz, Ryan P.
    Andrews, Kristin L.
    Bo, Yunxin Y.
    Booker, Shon K.
    Caenepeel, Sean
    Cee, Victor J.
    Noel, D'Angelo D.
    Freeman, Daniel J.
    Herberich, Bradley J.
    Hong, Fang-Tsao
    Jackson, Claire L. M.
    Jiang, Jian
    Lanman, Brian A.
    Liu, Longbin
    McCarter, John D.
    Mullady, Erin L.
    Nishimura, Nobuko
    Pettus, Liping H.
    Reed, Anthony B.
    San Miguel, Tisha
    Smith, Adrian L.
    Stec, Markian M.
    Tadesse, Seifu
    Tasker, Andrew S.
    Aidasani, Divesh
    Zhu, Xiaochun
    Subramanian, Raju
    Tamayo, Nuria A.
    Wang, Ling
    Whittington, Douglas A.
    Wu, Bin
    Wu, Tian
    Yang, Kevin
    Zalameda, Leeanne
    Zhang, Nancy
    Hughes, Paul E.
    Norman, Mark H.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [6] In vitro profiling of the potent and selective PI3K inhibitor AEZS-126
    Seipelt, Irene
    Gerlach, Matthias
    Blumenstein, Lars
    Mueller, Gilbert
    Teifel, Michael
    Polymeropoulos, Emmanuel
    Guenther, Eckhard
    [J]. CANCER RESEARCH, 2009, 69
  • [7] INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer
    Jessen, Katayoun A.
    Kessler, Linda
    Kucharski, Jeff
    Guo, Xin
    Staunton, Jocelyn
    Elia, Marikka
    Janes, Matthew
    Lan, Lucy
    Wang, Shunyou
    Stewart, Josh
    Darjania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Michael
    Ren, Pingda
    Fruman, David
    Rommel, Christian
    Liu, Yi
    [J]. CANCER RESEARCH, 2011, 71
  • [8] Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
    Erra, Montse
    Taltavull, Joan
    Greco, Angelique
    Javier Bernal, Francisco
    Francisco Caturla, Juan
    Gracia, Jordi
    Dominguez, Maria
    Sabate, Mar
    Paris, Stephane
    Soria, Salome
    Hernandez, Begona
    Armengol, Clara
    Cabedo, Judit
    Bravo, Monica
    Calama, Elena
    Miralpeix, Montserrat
    Lehner, Martin D.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 118 - 123
  • [9] Characterization of a potent inhibitor of class 1 phosphatidylinositide-3′-kinases (PI3K) in human glioma
    Clarke, Paul A.
    Guillard, Sandrine
    Di Stefano, Francesca
    Poele, Robert te
    Valenti, Melanie
    Brandon, Alexis de Haven
    Eccles, Sue
    Raynaud, Florence
    Workman, Paul
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3414S - 3414S
  • [10] Discovery of a novel and potent mutant-selective inhibitor of PI3Kα
    Gao, Mingming
    Qi, Chao
    Li, Zhentian
    Fan, Qipeng
    Wang, Liyang
    Zhou, Fei
    You, Lin
    Zheng, Hewen
    Li, Yu
    Wu, Liangxing
    Yao, Wenqing
    Liu, Phillip C.
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345